HARMONY BIOSCIENCES HOLDINGS
NASDAQ: HRMY (Harmony Biosciences Holdings, I)
Last update: 5 hours ago27.71
-0.03 (-0.11%)
| Previous Close | 27.74 |
| Open | 27.84 |
| Volume | 683,038 |
| Avg. Volume (3M) | 884,351 |
| Market Cap | 1,602,763,392 |
| Price / Earnings (TTM) | 10.23 |
| Price / Earnings (Forward) | 8.42 |
| Price / Sales | 1.87 |
| Price / Book | 1.84 |
| 52 Weeks Range | |
| Earnings Date | 5 May 2026 |
| Profit Margin | 20.50% |
| Operating Margin (TTM) | 30.45% |
| Diluted EPS (TTM) | 2.62 |
| Quarterly Revenue Growth (YOY) | 19.50% |
| Quarterly Earnings Growth (YOY) | 18.90% |
| Total Debt/Equity (MRQ) | 24.63% |
| Current Ratio (MRQ) | 3.67 |
| Operating Cash Flow (TTM) | 222.67 M |
| Levered Free Cash Flow (TTM) | 143.41 M |
| Return on Assets (TTM) | 12.81% |
| Return on Equity (TTM) | 24.71% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Harmony Biosciences Holdings, I | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | 1.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -0.5 |
| Average | 1.63 |
|
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 11.10% |
| % Held by Institutions | 92.80% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| American Century Companies Inc | 31 Dec 2025 | 1,841,672 |
| Lsv Asset Management | 31 Dec 2025 | 1,657,093 |
| Sg Americas Securities, Llc | 31 Dec 2025 | 961,667 |
| Aqr Capital Management Llc | 31 Dec 2025 | 813,889 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 55.00 (HC Wainwright & Co., 98.48%) | Buy |
| Median | 44.00 (58.79%) | |
| Low | 28.00 (B of A Securities, 1.05%) | Sell |
| Average | 41.60 (50.13%) | |
| Total | 3 Buy, 1 Hold, 1 Sell | |
| Avg. Price @ Call | 30.13 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| B of A Securities | 25 Feb 2026 | 28.00 (1.05%) | Sell | 28.19 |
| HC Wainwright & Co. | 25 Feb 2026 | 55.00 (98.48%) | Buy | 28.19 |
| Needham | 25 Feb 2026 | 44.00 (58.79%) | Buy | 28.19 |
| UBS | 25 Feb 2026 | 36.00 (29.92%) | Hold | 28.19 |
| 11 Feb 2026 | 46.00 (66.01%) | Hold | 36.59 | |
| Truist Securities | 08 Jan 2026 | 45.00 (62.40%) | Buy | 37.87 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 12 Jan 2026 | Announcement | Harmony Biosciences Guides to Over $1 Billion in WAKIX® Revenue in 2026; Advancing Robust Late-Stage Pipeline With Potential for Long-term Value Creation |
| 07 Jan 2026 | Announcement | Harmony Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |